3 Sales Growth Stocks to Buy as Q3 Earnings Get Underway

The article highlights BP, Intuitive Surgical and Chipotle as sales-growth picks, with projected 2026 sales growth of 28.9%, 16.7% and 9%, respectively; their Zacks ranks are #1, #2 and #2. The screen also requires cash flow above $500 million, above-industry historical sales growth and estimate revisions, operating margin above 5%, ROE above 5%, and a below-industry price-to-sales ratio. The recommendations are stock-selection commentary, while the article notes elevated Treasury yields, volatile oil prices, persistent inflation, tariff uncertainty and the risk of further Fed tightening.

Analysis

The screen conflates unlike forms of revenue growth. BP’s top line is highly exposed to realized oil and gas prices, product mix, and currency; a higher sales forecast can coexist with weaker unit economics or cash generation if prices reverse. Treat its growth figure as a commodity beta signal, not evidence of expanding demand. For CMG, the key test is whether sales gains come from transactions and restaurant productivity rather than price increases that risk traffic or value perception. For ISRG, procedure growth, system placements, and recurring instruments/accessories are more informative than aggregate sales: a growing installed base can compound recurring revenue, but hospital budgets, utilization, and competition from Medtronic and other surgical-robotics platforms remain constraints.

Over the next few weeks, earnings guidance and estimate revisions can drive dispersion; over 6–18 months, the quality and repeatability of growth matter more than the screen’s headline ranking. Higher rates also raise the hurdle for long-duration growth valuations, particularly ISRG, while a sharp oil-price decline would undermine BP’s nominal growth and cash-flow outlook. The contrarian point: sales growth is not inherently a safer metric than earnings—BP’s forecast may be mostly price, while CMG or ISRG could deliver better underlying volume with slower reported growth. No outright buy follows from the screen alone; verify organic volumes, margins, and valuation before sizing.

Key Decisions for Investors

• Do not trade the three names as a single ‘growth’ basket. Ahead of each report, compare actual organic volume/procedure growth and operating-margin direction with revenue growth; avoid adding on a sales beat alone.
• Watch BP as a conditional commodity exposure, not a structural growth position. Reassess if realized prices, production, or cash-flow guidance weaken; a sustained oil-price decline would falsify the bullish top-line case.
• Keep ISRG on an earnings watchlist: constructive confirmation would be procedure growth and recurring instrument revenue holding up alongside system placements. Falsifiers include weaker utilization, hospital spending delays, or margin pressure; valuation data are needed before recommending an entry.
• For CMG, monitor comparable-store sales split between transactions and pricing, plus restaurant-level margin commentary. If sales rely increasingly on price while traffic softens, reduce exposure; sustained transaction growth with stable margins would support a more constructive view.